Ciclopirox Olamine Exerts Tumor-Suppressor Effects via Topoisomerase II Alpha in Lung Adenocarcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ciclopirox Olamine Exerts Tumor-Suppressor Effects via Topoisomerase II Alpha in Lung Adenocarcinoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-02-18
DOI
10.3389/fonc.2022.791916
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues
- (2021) Áron Bartha et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
- (2021) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy
- (2021) Firas Al-Zubaydi et al. Drug Delivery and Translational Research
- Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression
- (2020) Wook Jin Journal of Clinical Medicine
- Controversies and challenges in the histologic subtyping of lung adenocarcinoma
- (2020) Kelly J. Butnor Translational Lung Cancer Research
- Correction: Ciclopirox activates PERK-dependent endoplasmic reticulum stress to drive cell death in colorectal cancer
- (2020) Jianjun Qi et al. Cell Death & Disease
- Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia
- (2020) Y. Gong et al. Experimental Oncology
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment for Urothelial Cancers in Rats and Dogs
- (2019) Scott J Weir et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Prognostic significance of TOP2A in non-small cell lung cancer revealed by bioinformatic analysis
- (2019) Wenxia Ma et al. Cancer Cell International
- Current Diagnosis and Management of Small-Cell Lung Cancer
- (2019) Shuhang Wang et al. MAYO CLINIC PROCEEDINGS
- Gene Expression Signature-Based Approach Identifies Antifungal Drug Ciclopirox As a Novel Inhibitor of HMGA2 in Colorectal Cancer
- (2019) Yu-Min Huang et al. Biomolecules
- TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway
- (2018) Yao-fei Pei et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- New insights into diagnosis and therapeutic options for proliferative hepatoblastoma
- (2018) Katarzyna B. Hooks et al. HEPATOLOGY
- Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A
- (2018) Rui Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches
- (2018) Wei Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Osimertinib as First-Line Treatment in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2018) Sanjay Popat NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of tumor related signaling pathways with known compounds to determine potential agents for lung adenocarcinoma
- (2018) Song Xu et al. Thoracic Cancer
- DNA damage and apoptosis induced by a potent orally podophyllotoxin derivative in breast cancer
- (2018) Yajie Wang et al. Cell Communication and Signaling
- ROS and the DNA damage response in cancer
- (2018) Upadhyayula Sai Srinivas et al. Redox Biology
- Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients
- (2017) Gregory M. Heestand et al. EUROPEAN JOURNAL OF CANCER
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
- (2017) Julie R Brahmer et al. LANCET ONCOLOGY
- Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK
- (2016) Hongyu Zhou et al. BIOCHEMICAL PHARMACOLOGY
- Repositioning the Old Fungicide Ciclopirox for New Medical Uses
- (2016) Tao Shen et al. CURRENT PHARMACEUTICAL DESIGN
- Antileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition β-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell Lines
- (2016) Jianrong Wu et al. PLoS One
- Effects of Olive Metabolites on DNA Cleavage Mediated by Human Type II Topoisomerases
- (2015) Kendra R. Vann et al. BIOCHEMISTRY
- Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours - A prognostic test after surgical resection
- (2015) Matthias Kolberg et al. Molecular Oncology
- A Hypusine-eIF5A-PEAK1 Switch Regulates the Pathogenesis of Pancreatic Cancer
- (2014) K. Fujimura et al. CANCER RESEARCH
- Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies
- (2013) Mark D. Minden et al. AMERICAN JOURNAL OF HEMATOLOGY
- Blocking eIF5A Modification in Cervical Cancer Cells Alters the Expression of Cancer-Related Genes and Suppresses Cell Proliferation
- (2013) Elisabeth Mémin et al. CANCER RESEARCH
- Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity
- (2013) Siddhartha Sen et al. EXPERIMENTAL HEMATOLOGY
- Hemochromatosis Enhances Tumor Progression via Upregulation of Intracellular Iron in Head and Neck Cancer
- (2013) Michelle Lenarduzzi et al. PLoS One
- Target genes of Topoisomerase II regulate neuronal survival and are defined by their chromatin state
- (2012) V. K. Tiwari et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Wnt Inhibitor Screen Reveals Iron Dependence of -Catenin Signaling in Cancers
- (2011) S. Song et al. CANCER RESEARCH
- The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway
- (2011) Y Luo et al. ONCOGENE
- ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
- (2010) J. C. Brase et al. CLINICAL CANCER RESEARCH
- The antitumor activity of the fungicide ciclopirox
- (2010) Hongyu Zhou et al. INTERNATIONAL JOURNAL OF CANCER
- Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells
- (2009) Y. Eberhard et al. BLOOD
- DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
- (2009) Yves Pommier CHEMICAL REVIEWS
- Targeting Wnt pathway in lymphoma and myeloma cells
- (2008) Matthias Schmidt et al. BRITISH JOURNAL OF HAEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search